

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTION PASSED AT THE 6TH SUPERVISORY COMMITTEE MEETING FOR FY2024

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 26 November 2024, the Company duly convened its 6th supervisory committee (the “**Supervisory Committee**”) meeting for the financial year ending 31 December 2024 (“**FY2024**”) via teleconference. The full Supervisory Committee, comprising three (3) members, was present. The said meeting was convened in compliance with the Articles of Association of the Company. The following resolution was discussed and passed:

1. That the proposed appointment of Ms. Xie Xi (谢希) as a member of the Supervisory Committee of the Company, be approved.

Given that the term of office of Mr. Xing Jianhua (幸建华) as a Supervisor of the Company is expiring soon, and he intends to resign from his position as a Supervisor of the Company, the Supervisory Committee has nominated and recommended Ms. Xie Xi as a Supervisor of the Company, for a term of office lasting until the conclusion of the current Supervisory Committee's term. In accordance with the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association of the Company, given that Mr. Xing Jianhua's resignation will cause the number of supervisors of the Company to fall below the statutory minimum, his resignation shall take effect upon the appointment of a new supervisor at a general meeting of the Company. Until the newly appointed supervisor assumes office, Mr. Xing Jianhua shall continue to perform his duties as a Supervisor of the Company in compliance with relevant laws and regulations.

Ms. Xie Xi, born in May 1986, holds a Bachelor of Economics and a Master of Business Administration. From July 2008 to March 2022, she successively held positions within the Company as an Accountant in the Finance Department, Assistant to the Head of the Finance Department, Securities Affairs Representative, Deputy Head of the Finance Department, and Head of the Finance Department. Since March 2022, she has been serving as Deputy General Manager of the Finance Department of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司).

The above resolution shall be tabled for shareholders' approval at a general meeting of the Company to be convened in due course.

By order of the Board

Jiao Yan
Secretary to the Board of Directors
26 November 2024